Pressmeddelande -
Five GU Ventures portfolio companies represented at the world’s leading healthcare conference in San Francisco
.............................................................
GU Ventures shares news and updates about its operations, portfolio companies, and alumni companies:
..............................................................
Five GU Ventures portfolio companies participated this week in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco – one of the world’s most influential meeting places for life science, biotech, and healthcare investment.
The conference is invitation-only and brings together global industry leaders, high-growth companies, investors, and strategic partners for top-level meetings, partnership discussions, and business development.
“We are very pleased to see several of our companies represented among the Swedish participants at the world’s leading healthcare conference in the United States. This reflects both the high quality of the research being commercialised at the University of Gothenburg and the international relevance of the companies emerging from our ecosystem. When our companies take part in forums such as the J.P. Morgan Healthcare Conference, important opportunities are created for partnerships, investments, and continued global growth,” says Klementina Österberg, CEO of GU Ventures.
The five GU Ventures companies represented on site are:
Alzinova
Alzinova develops treatments for Alzheimer’s disease. With its lead candidate ALZ-101, a therapeutic vaccine based on the patented AβCC peptide technology, the company has recently received both IND approval and Fast Track designation from the U.S. Food and Drug Administration (FDA) ahead of Phase II clinical trials. This represents a strong regulatory endorsement that further strengthens the company’s international position.
Webbsida: https://www.alzinova.com/
MucoLife Therapeutics
MucoLife Therapeutics is developing the innovative drug candidate MLT-001 for the treatment of cystic fibrosis and COPD—diseases affecting more than 500 million people globally. The company originates from world-leading mucus research at the University of Gothenburg and combines over 40 years of academic research with industrial experience from, among others, AstraZeneca and Novartis.
Följ MucoLife Therapeutics på Linkedin HÄR
Webbsida: https://mucolife.com/
Cereno Scientific
Cereno Scientific develops disease-modifying therapies for rare cardiovascular and pulmonary diseases. The company’s lead drug candidate, CS1, an epigenetic HDAC inhibitor, has demonstrated promising efficacy signals in clinical studies in pulmonary arterial hypertension (PAH), including improved cardiac function and quality of life.
In addition to CS1, Cereno is also advancing CS014, which has recently shown a favourable safety and tolerability profile in Phase I, as well as a preclinical programme with CS585 aimed at future treatments in cardiovascular and pulmonary diseases. The company is headquartered in Gothenburg and also has operations in the United States.
Följ Cereno Scientific på Linkedin HÄR
Webbsida: https://cerenoscientific.se/
OnDosis
OnDosis aims to revolutionise how patients take their medications. The company has developed a patented technology platform based on a connected, handheld dosing device that enables personalised, precise, and user-friendly dosing of oral medicines.
By combining traditional pharmaceuticals with digital solutions and data-driven dose adjustment, OnDosis strives to ensure that patients receive the right dose at the right time, leading to improved treatment outcomes and quality of life.
Webbsida: www.ondosis.com
Aventix
Aventix utvecklar avancerade sensorer och AI-baserade analyslösningar för laboratorier och forskningsmiljöer. Under konferensen deltar bolagets vd Erik Gatenholm i möten med potentiella partners och kunder för att diskutera hur Aventix teknologi kan möjliggöra bättre datainsamling och analys inom life science och forskning.
Webbsida: https://aventix.io/
GU Ventures – a driving force for Life Science innovation
GU Ventures is the holding company of the University of Gothenburg and a leading Swedish investor and incubator for research-based companies with global potential. Within Life Science, GU Ventures has extensive experience in building, financing, and supporting companies in biotechnology, pharmaceuticals, and medical technology—from academic research to international markets.
The Life Science companies in the GU Ventures ecosystem benefit from the strong research environment in Western Sweden, with close ties to the University of Gothenburg, the Sahlgrenska Academy, and a well-developed innovation and industry cluster.
That three portfolio companies were represented at the J.P. Morgan Healthcare Conference demonstrates the international relevance and growth potential of the research and innovation emerging from the GU Ventures environment.
Ämnen
Kategorier
Om GU Ventures AB
GU Ventures bygger företag av banbrytande idéer som kan forma en bättre morgondag och är topprankad av UBI Global Index som en av världens 20 ledande universitetsdrivna inkubatorer. Vi finansierar och utvecklar nya innovativa affärsidéer med kopplingar till Göteborgs universitet, som är ett av norra Europas största universitet. Vårt uppdrag är att kommersialisera dessa innovationer, så att det leder till användning av forskning och kompetens, förnyelse av näringslivet, skapande av jobb och hållbar tillväxt. Vårt passionerade team av företagsbyggare, finansexperter, IP och juridisk talang supporterar dedikerat våra företag och säkerställer deras framgång.
Sedan startpunkten 1995 har GU Ventures utvecklat över 240 nya affärsidéer, varav 140 bedriver verksamhet idag och varav 15 är listade. Vår portfölj består av 80-tal innehav och ett antal projekt.
I den senaste undersökningen matchar 87% av företagen de globala hållbarhetsmål som ställts av FN. GU Ventures ägs helt av den svenska staten och förvaltas av Göteborgs universitet. Läs gärna mer på: www.guventures.com.
